Press Release Prescribing Information
Campath® Alemtuzumab - For Intravenous Use Only
SEARCH
   HCP Home  |  Full Prescribing Information (PDF)  |  Contact Us  |  Site Map  
As a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL) - See Things in a Whole New Light: Campath First Line - Campath® Alemtuzumab For Intravenous Use Only
Print | Text Size:

 

Reimbursement Support Line

Bayer HealthCare Pharmaceuticals Oncology offers services to help providers and patients with product-related reimbursement questions. Reimbursement consultants can be reached at the Bayer HealthCare Pharmaceuticals Oncology Reimbursement Support Line: 1-800-321-4669 (9 AM to 5 PM ET, Monday through Friday).

Services Overview
The Reimbursement Support Line team has experience across all payer types, including Medicare. The team closely monitors policy changes, such as recent Medicare reform, to provide accurate and timely information. Questions answered by the team are wide-ranging, but typically can be classified into one of the following groups:

The On-Call Team helps ensure that the Reimbursement Support Line provides the highest level of reimbursement support and patient assistance. The team closely monitors the reimbursement environments for the latest changes in Medicare, Medicaid, and private payer reimbursement and coverage policies. The result is a knowledgeable staff capable of answering calls, processing patient-assistance applications, and providing product-specific support to the provider and patient communities.

*It is the responsibility of the provider to choose the most appropriate code as documented in the patient’s medical chart. Using the assistance of the Reimbursement Support Line in no way guarantees reimbursement.

Indication and Important Safety Information

Campath is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL).

WARNING: CYTOPENIAS, INFUSION REACTIONS, and INFECTIONS

Cytopenias: Serious, including fatal, pancytopenia/marrow hypoplasia, autoimmune idiopathic thrombocytopenia, and autoimmune hemolytic anemia can occur in patients receiving Campath. Single doses of Campath greater than 30 mg or cumulative doses greater than 90 mg per week increase the incidence of pancytopenia [see WARNINGS AND PRECAUTIONS (5.1)].

Infusion Reactions: Campath administration can result in serious, including fatal, infusion reactions. Carefully monitor patients during infusions and withhold Campath for Grade 3 or 4 infusion reactions. Gradually escalate Campath to the recommended dose at the initiation of therapy and after interruption of therapy for 7 or more days [see DOSAGE AND ADMINISTRATION (2) and WARNINGS AND PRECAUTIONS (5.2)].

Infections: Serious, including fatal, bacterial, viral, fungal, and protozoan infections can occur in patients receiving Campath. Administer prophylaxis against Pneumocystis jiroveci pneumonia (PCP) and herpes virus infections [see DOSAGE AND ADMINISTRATION (2.2) and WARNINGS AND PRECAUTIONS (5.3)].

The most commonly reported adverse reactions are infusion reactions fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections. See "Warnings and Precautions," and "Adverse Reactions" sections of full Prescribing Information.

Please see Full Prescribing Information (PDF).